The so called “major depression“ in the course of disseminated cancer with multiple metastases

Leszek Tomász Ros

2004, Number 4

<< Back Next >>

Med Crit 2004; 18 (4)

The so called “major depression“ in the course of disseminated cancer with multiple metastases

Leszek Tomasz Ros

Full text

How to cite this article

Language: Spanish
References: 9
Page: 127-129
PDF size: 44.30 Kb.

ABSTRACT

Many authors prove through the examples of their patients that Sertraline is a most efficient drug best accepted in the treatment of the “major depression” while patient has the cancer with multiple metastases. We present the case of a trainer of gymnastics.

REFERENCES

Aguglia E, Casacchia M, Cassano GB. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International Clinical Psychopharmacology 1993;8(3):197-202.
Finkel SL, Richter EM, Clary CM. Comparative efficiency and safety of sertraline versus nortriptyline in major depression in patients 70 and older. International Psychogeriatrics 1999;11(l):85-99.
Keller MB, Gelenberg AJ, Hirschfeld RM. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry 1998;59(11):598-607.
Keller MB, Harrison W, Fawcett JA. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of under treatment in the community. Psychopharmacology Bullettin 1995;31(2):10.
Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in post psychotic depressive disorder of schizophrenia. Schizophrenia research 1998;33(1-2):7.
Moller HJ, Gallinat J, Hegerl U. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1988;31(6):170-7.
Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive compulsive disorder. [Review] [72 refs]. Drugs 1992;44(4): 604-24.
Oinan TG. Lithium augmentation in sertraline – resistant depression: a preliminary dose – response study. Psychiatrica Scandinavica 1993;88(4):300-1.
Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. [Review] [55 refs]. International Clinical Psychopharmacology 1996;10(3):129-41.